Tag #Aja001

What unique challenges does the botanical nature of AJA001 present in the FDA approval process?

The development of AJA001 leverages patented genetics from Charlotte's Web and builds upon the success of Epidiolex, the only FDA-approved non-synthetic cannabis drug. The unique challenges of botanical drug development, particularly the complexities of chemistry manufacturing controls for full-spectrum cannabis, are addressed by a team with extensive experience in this area. This collaboration underscores the growing convergence of medical cannabis and pharmaceutical industries.